ROAS 10 - Pharmacom Labs

Isotretinoin, derived from retinoic acid, targets severe acne by shrinking sebaceous glands and cutting sebum production. Released in 1982 as Accutane by Hoffmann-La Roche, it quickly became the go-to for stubborn skin conditions that resist other therapies. Its powerful effects necessitate close monitoring due to significant risks, especially teratogenicity. Patients using isotretinoin must adhere to strict protocols, ensuring safety throughout the course. Known for its high efficacy, it remains a leading solution for controlling severe acne when milder options prove insufficient​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about ROAS 10 by Pharmacom Labs, consult with your doctor or healthcare professional.